EU Approves Sanofi's Sarclisa Subcutaneous Formulation for Multiple Myeloma

The European Commission has approved Sanofi's Sarclisa (isatuximab) for subcutaneous administration in multiple myeloma patients. This marks the first anticancer therapy in the EU to be delivered via an on-body injector or manual subcutaneous injection. The new formulation offers greater flexibility, potentially allowing for home or outpatient treatment, based on its demonstrated non-inferiority to the intravenous version.